Download PDF
Semin Thromb Hemost 2010; 36(3): 309-320
DOI: 10.1055/s-0030-1253453
© Thieme Medical Publishers

Placental Vasculature in Health and Disease

Eliyahu V. Khankin1 , Caroline Royle1 , S. Ananth Karumanchi1 , 2
  • 1Department of Medicine, Obstetrics & Gynecology and Center for Vascular Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
  • 2Howard Hughes Medical Institute, Boston, Massachusetts
Further Information

Publication History

Publication Date:
20 May 2010 (online)

    Permissions and Reprints

ABSTRACT

Both angiogenesis and vasculogenesis occur during normal placental development. Additionally, the placenta undergoes a process of vascular mimicry (also referred to as pseudo-vasculogenesis) where the placental cytotrophoblasts that invade the spiral arteries convert from an epithelial to an endothelial phenotype during normal pregnancy. Failure of placental angiogenesis and pseudo-vasculogenesis during placental development has been linked to the pathogenesis of preeclampsia and related disorders such as intrauterine growth restriction. This review discusses placental vascular development during health and in disease with a focus on accumulating recent evidence that the maternal clinical syndrome of preeclampsia may be due to the result of excess antiangiogenic factors liberated by the diseased placenta.

KEYWORDS

Angiogenesis - hypertension - vascular endothelial growth factor - placental growth factor - preeclampsia

REFERENCES

  • 1 Risau W, Flamme I. Vasculogenesis.  Annu Rev Cell Dev Biol. 1995;  11 73-91
    CrossrefPubMedGoogle Scholar
  • 2 Risau W. Mechanisms of angiogenesis.  Nature. 1997;  386(6626) 671-674
    CrossrefPubMedGoogle Scholar
  • 3 Demir R, Kaufmann P, Castellucci M, Erbengi T, Kotowski A. Fetal vasculogenesis and angiogenesis in human placental villi.  Acta Anat (Basel). 1989;  136(3) 190-203
    CrossrefPubMedGoogle Scholar
  • 4 Cross J C, Werb Z, Fisher S J. Implantation and the placenta: key pieces of the development puzzle.  Science. 1994;  266(5190) 1508-1518
    CrossrefPubMedGoogle Scholar
  • 5 Genbacev O, Zhou Y, Ludlow J W, Fisher S J. Regulation of human placental development by oxygen tension.  Science. 1997;  277(5332) 1669-1672
    CrossrefPubMedGoogle Scholar
  • 6 Zhou Y, Fisher S J, Janatpour M et al.. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?.  J Clin Invest. 1997;  99(9) 2139-2151
    CrossrefPubMedGoogle Scholar
  • 7 Jaffe R. First trimester utero-placental circulation: maternal-fetal interaction.  J Perinat Med. 1998;  26(3) 168-174
    PubMedGoogle Scholar
  • 8 Roth I, Fisher S J. IL-10 is an autocrine inhibitor of human placental cytotrophoblast MMP-9 production and invasion.  Dev Biol. 1999;  205(1) 194-204
    CrossrefPubMedGoogle Scholar
  • 9 Lim K H, Zhou Y, Janatpour M et al.. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia.  Am J Pathol. 1997;  151(6) 1809-1818
    PubMedGoogle Scholar
  • 10 Brosens I A, Robertson W B, Dixon H G. The role of the spiral arteries in the pathogenesis of preeclampsia.  Obstet Gynecol Annu. 1972;  1 177-191
    PubMedGoogle Scholar
  • 11 Hanna J, Goldman-Wohl D, Hamani Y et al.. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface.  Nat Med. 2006;  12(9) 1065-1074
    CrossrefPubMedGoogle Scholar
  • 12 Kohnen G, Kertschanska S, Demir R, Kaufmann P. Placental villous stroma as a model system for myofibroblast differentiation.  Histochem Cell Biol. 1996;  105(6) 415-429
    CrossrefPubMedGoogle Scholar
  • 13 Kaufmann P, Bruns U, Leiser R, Luckhardt M, Winterhager E. The fetal vascularisation of term human placental villi. II. Intermediate and terminal villi.  Anat Embryol (Berl). 1985;  173(2) 203-214
    CrossrefPubMedGoogle Scholar
  • 14 Kaufmann P, Luckhardt M, Schweikhart G, Cantle S J. Cross-sectional features and three-dimensional structure of human placental villi.  Placenta. 1987;  8(3) 235-247
    CrossrefPubMedGoogle Scholar
  • 15 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor.  Endocr Rev. 1997;  18(1) 4-25
    CrossrefPubMedGoogle Scholar
  • 16 Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.  Cell Struct Funct. 2001;  26(1) 25-35
    CrossrefPubMedGoogle Scholar
  • 17 Persico M G, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF).  Curr Top Microbiol Immunol. 1999;  237 31-40
    PubMedGoogle Scholar
  • 18 Carmeliet P, Moons L, Luttun A et al.. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.  Nat Med. 2001;  7(5) 575-583
    CrossrefPubMedGoogle Scholar
  • 19 Charnock-Jones D S, Burton G J. Placental vascular morphogenesis.  Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;  14(6) 953-968
    CrossrefPubMedGoogle Scholar
  • 20 Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis.  Physiol Rev. 2002;  82(3) 673-700
    PubMedGoogle Scholar
  • 21 Olofsson B, Jeltsch M, Eriksson U, Alitalo K. Current biology of VEGF-B and VEGF-C.  Curr Opin Biotechnol. 1999;  10(6) 528-535
    CrossrefPubMedGoogle Scholar
  • 22 Kendall R L, Thomas K A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.  Proc Natl Acad Sci U S A. 1993;  90(22) 10705-10709
    CrossrefPubMedGoogle Scholar
  • 23 He Y, Smith S K, Day K A, Clark D E, Licence D R, Charnock-Jones D S. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity.  Mol Endocrinol. 1999;  13(4) 537-545
    CrossrefPubMedGoogle Scholar
  • 24 Papapetropoulos A, García-Cardeña G, Dengler T J, Maisonpierre P C, Yancopoulos G D, Sessa W C. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.  Lab Invest. 1999;  79(2) 213-223
    CrossrefPubMedGoogle Scholar
  • 25 Koblizek T I, Weiss C, Yancopoulos G D, Deutsch U, Risau W. Angiopoietin-1 induces sprouting angiogenesis in vitro.  Curr Biol. 1998;  8(9) 529-532
    CrossrefPubMedGoogle Scholar
  • 26 Davis S, Aldrich T H, Jones P F et al.. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.  Cell. 1996;  87(7) 1161-1169
    CrossrefPubMedGoogle Scholar
  • 27 Carmeliet P. Mechanisms of angiogenesis and arteriogenesis.  Nat Med. 2000;  6(4) 389-395
    CrossrefPubMedGoogle Scholar
  • 28 Thurston G, Rudge J S, Ioffe E et al.. Angiopoietin-1 protects the adult vasculature against plasma leakage.  Nat Med. 2000;  6(4) 460-463
    CrossrefPubMedGoogle Scholar
  • 29 Thurston G, Suri C, Smith K et al.. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1.  Science. 1999;  286(5449) 2511-2514
    CrossrefPubMedGoogle Scholar
  • 30 Stratmann A, Acker T, Burger A M, Amann K, Risau W, Plate K H. Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.  Int J Cancer. 2001;  91(3) 273-282
    CrossrefPubMedGoogle Scholar
  • 31 Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands J R. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma.  J Clin Invest. 1999;  103(3) 341-345
    CrossrefPubMedGoogle Scholar
  • 32 Maisonpierre P C, Suri C, Jones P F et al.. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.  Science. 1997;  277(5322) 55-60
    CrossrefPubMedGoogle Scholar
  • 33 Wulff C, Wilson H, Dickson S E, Wiegand S J, Fraser H M. Hemochorial placentation in the primate: expression of vascular endothelial growth factor, angiopoietins, and their receptors throughout pregnancy.  Biol Reprod. 2002;  66(3) 802-812
    CrossrefPubMedGoogle Scholar
  • 34 Charnock-Jones D S, Sharkey A M, Boocock C A et al.. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells.  Biol Reprod. 1994;  51(3) 524-530
    CrossrefPubMedGoogle Scholar
  • 35 Cooper J C, Sharkey A M, McLaren J, Charnock-Jones D S, Smith S K. Localization of vascular endothelial growth factor and its receptor, flt, in human placenta and decidua by immunohistochemistry.  J Reprod Fertil. 1995;  105(2) 205-213
    CrossrefPubMedGoogle Scholar
  • 36 Geva E, Ginzinger D G, Zaloudek C J, Moore D H, Byrne A, Jaffe R B. Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2.  J Clin Endocrinol Metab. 2002;  87(9) 4213-4224
    CrossrefPubMedGoogle Scholar
  • 37 Clark D E, Smith S K, Sharkey A M, Charnock-Jones D S. Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy.  Hum Reprod. 1996;  11(5) 1090-1098
    PubMedGoogle Scholar
  • 38 Zhou Y, McMaster M, Woo K et al.. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome.  Am J Pathol. 2002;  160(4) 1405-1423
    PubMedGoogle Scholar
  • 39 Hildebrandt V A, Babischkin J S, Koos R D, Pepe G J, Albrecht E D. Developmental regulation of vascular endothelial growth/permeability factor messenger ribonucleic acid levels in and vascularization of the villous placenta during baboon pregnancy.  Endocrinology. 2001;  142(5) 2050-2057
    CrossrefPubMedGoogle Scholar
  • 40 Shalaby F, Rossant J, Yamaguchi T P et al.. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.  Nature. 1995;  376(6535) 62-66
    CrossrefPubMedGoogle Scholar
  • 41 Fong G H, Rossant J, Gertsenstein M, Breitman M L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.  Nature. 1995;  376(6535) 66-70
    CrossrefPubMedGoogle Scholar
  • 42 Ain R, Canham L N, Soares M J. Gestation stage-dependent intrauterine trophoblast cell invasion in the rat and mouse: novel endocrine phenotype and regulation.  Dev Biol. 2003;  260(1) 176-190
    CrossrefPubMedGoogle Scholar
  • 43 Zhou Y, Bellingard V, Feng K T, McMaster M, Fisher S J. Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PlGF, and VEGF-C.  Dev Biol. 2003;  263(1) 114-125
    CrossrefPubMedGoogle Scholar
  • 44 Rowe A J, Wulff C, Fraser H M. Localization of mRNA for vascular endothelial growth factor (VEGF), angiopoietins and their receptors during the peri-implantation period and early pregnancy in marmosets (Callithrix jacchus).  Reproduction. 2003;  126(2) 227-238
    CrossrefPubMedGoogle Scholar
  • 45 Dunk C, Shams M, Nijjar S et al.. Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development.  Am J Pathol. 2000;  156(6) 2185-2199
    CrossrefPubMedGoogle Scholar
  • 46 Zhang E G, Smith S K, Baker P N, Charnock-Jones D S. The regulation and localization of angiopoietin-1, -2, and their receptor Tie2 in normal and pathologic human placentae.  Mol Med. 2001;  7(9) 624-635
    PubMedGoogle Scholar
  • 47 Goldman-Wohl D S, Ariel I, Greenfield C, Lavy Y, Yagel S. Tie-2 and angiopoietin-2 expression at the fetal-maternal interface: a receptor ligand model for vascular remodelling.  Mol Hum Reprod. 2000;  6(1) 81-87
    CrossrefPubMedGoogle Scholar
  • 48 Clark D E, Smith S K, He Y et al.. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation.  Biol Reprod. 1998;  59(6) 1540-1548
    CrossrefPubMedGoogle Scholar
  • 49 Bdolah Y, Sukhatme V P, Karumanchi S A. Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights.  Semin Nephrol. 2004;  24(6) 548-556
    CrossrefPubMedGoogle Scholar
  • 50 Walker J J. Pre-eclampsia.  Lancet. 2000;  356(9237) 1260-1265
    CrossrefPubMedGoogle Scholar
  • 51 Page E W. The relation between hydatid moles, relative ischemia of the gravid uterus and the placental origin of eclampsia.  Am J Obstet Gynecol. 1939;  37 291-293
    PubMedGoogle Scholar
  • 52 Red-Horse K, Zhou Y, Genbacev O et al.. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface.  J Clin Invest. 2004;  114(6) 744-754
    CrossrefPubMedGoogle Scholar
  • 53 Zhou Y, Damsky C H, Fisher S J. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?.  J Clin Invest. 1997;  99(9) 2152-2164
    CrossrefPubMedGoogle Scholar
  • 54 Moldenhauer J S, Stanek J, Warshak C, Khoury J, Sibai B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent.  Am J Obstet Gynecol. 2003;  189(4) 1173-1177
    CrossrefPubMedGoogle Scholar
  • 55 Harrington K, Cooper D, Lees C, Hecher K, Campbell S. Doppler ultrasound of the uterine arteries: the importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby.  Ultrasound Obstet Gynecol. 1996;  7(3) 182-188
    CrossrefPubMedGoogle Scholar
  • 56 Makris A, Thornton C, Thompson J et al.. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1.  Kidney Int. 2007;  71(10) 977-984
    CrossrefPubMedGoogle Scholar
  • 57 Roberts J M, Taylor R N, Musci T J, Rodgers G M, Hubel C A, McLaughlin M K. Preeclampsia: an endothelial cell disorder.  Am J Obstet Gynecol. 1989;  161(5) 1200-1204
    PubMedGoogle Scholar
  • 58 Ferris T F. Pregnancy, preeclampsia, and the endothelial cell.  N Engl J Med. 1991;  325(20) 1439-1440
    CrossrefPubMedGoogle Scholar
  • 59 Roberts J M. Endothelial dysfunction in preeclampsia.  Semin Reprod Endocrinol. 1998;  16(1) 5-15
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Fisher K A, Luger A, Spargo B H, Lindheimer M D. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis.  Medicine (Baltimore). 1981;  60(4) 267-276
    CrossrefPubMedGoogle Scholar
  • 61 Thorp Jr J M, White II G C, Moake J L, Bowes Jr W A. von Willebrand factor multimeric levels and patterns in patients with severe preeclampsia.  Obstet Gynecol. 1990;  75(2) 163-167
    PubMedGoogle Scholar
  • 62 Redman C W, Sacks G P, Sargent I L. Preeclampsia: an excessive maternal inflammatory response to pregnancy.  Am J Obstet Gynecol. 1999;  180(2 Pt 1) 499-506
    CrossrefPubMedGoogle Scholar
  • 63 Calvin S, Corrigan J, Weinstein L, Jeter M. Factor VIII: von Willebrand factor patterns in the plasma of patients with pre-eclampsia.  Am J Perinatol. 1988;  5(1) 29-32
    Article in Thieme ConnectPubMedGoogle Scholar
  • 64 Lockwood C J, Peters J H. Increased plasma levels of ED1 + cellular fibronectin precede the clinical signs of preeclampsia.  Am J Obstet Gynecol. 1990;  162(2) 358-362
    PubMedGoogle Scholar
  • 65 Friedman S A, de Groot C J, Taylor R N, Golditch B D, Roberts J M. Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation.  Am J Obstet Gynecol. 1994;  170(3) 838-841
    PubMedGoogle Scholar
  • 66 Taylor R N, Crombleholme W R, Friedman S A, Jones L A, Casal D C, Roberts J M. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone.  Am J Obstet Gynecol. 1991;  165(4 Pt 1) 895-901
    PubMedGoogle Scholar
  • 67 Minakami H, Takahashi T, Izumi A, Tamada T. Increased levels of plasma thrombomodulin in preeclampsia.  Gynecol Obstet Invest. 1993;  36(4) 208-210
    CrossrefPubMedGoogle Scholar
  • 68 Boffa M C, Valsecchi L, Fausto A et al.. Predictive value of plasma thrombomodulin in preeclampsia and gestational hypertension.  Thromb Haemost. 1998;  79(6) 1092-1095
    PubMedGoogle Scholar
  • 69 Mills J L, DerSimonian R, Raymond E et al.. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study.  JAMA. 1999;  282(4) 356-362
    CrossrefPubMedGoogle Scholar
  • 70 Roberts J M, Edep M E, Goldfien A, Taylor R N. Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro: morphological and biochemical evidence.  Am J Reprod Immunol. 1992;  27(3–4) 101-108
    PubMedGoogle Scholar
  • 71 Roberts J M. Preeclampsia: what we know and what we do not know.  Semin Perinatol. 2000;  24(1) 24-28
    CrossrefPubMedGoogle Scholar
  • 72 Hasan K M, Manyonda I T, Ng F S, Singer D R, Antonios T F. Skin capillary density changes in normal pregnancy and pre-eclampsia.  J Hypertens. 2002;  20(12) 2439-2443
    CrossrefPubMedGoogle Scholar
  • 73 Jónsdóttir L S, Arngrímsson R, Geirsson R T, Sigvaldason H, Sigfússon N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy.  Acta Obstet Gynecol Scand. 1995;  74(10) 772-776
    CrossrefPubMedGoogle Scholar
  • 74 Maynard S E, Min J Y, Merchan J et al.. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.  J Clin Invest. 2003;  111(5) 649-658
    CrossrefPubMedGoogle Scholar
  • 75 Levine R J, Maynard S E, Qian C et al.. Circulating angiogenic factors and the risk of preeclampsia.  N Engl J Med. 2004;  350(7) 672-683
    CrossrefPubMedGoogle Scholar
  • 76 Polliotti B M, Fry A G, Saller D N, Mooney R A, Cox C, Miller R K. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia.  Obstet Gynecol. 2003;  101(6) 1266-1274
    CrossrefPubMedGoogle Scholar
  • 77 Tsatsaris V, Goffin F, Munaut C et al.. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences.  J Clin Endocrinol Metab. 2003;  88(11) 5555-5563
    CrossrefPubMedGoogle Scholar
  • 78 Bujold E, Romero R, Chaiworapongsa T et al.. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin.  J Matern Fetal Neonatal Med. 2005;  18(1) 9-16
    CrossrefPubMedGoogle Scholar
  • 79 Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia.  Circ Res. 2004;  95(9) 884-891
    CrossrefPubMedGoogle Scholar
  • 80 Levine R J, Thadhani R, Qian C et al.. Urinary placental growth factor and risk of preeclampsia.  JAMA. 2005;  293(1) 77-85
    CrossrefPubMedGoogle Scholar
  • 81 Levine R J, Lam C, Qian C CPEP Study Group et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.  N Engl J Med. 2006;  355(10) 992-1005
    CrossrefPubMedGoogle Scholar
  • 82 Venkatesha S, Toporsian M, Lam C et al.. Soluble endoglin contributes to the pathogenesis of preeclampsia.  Nat Med. 2006;  12(6) 642-649
    CrossrefPubMedGoogle Scholar
  • 83 Kusanovic J P, Romero R, Chaiworapongsa T et al.. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.  J Matern Fetal Neonatal Med. 2009;  22(11) 1021-1038
    CrossrefPubMedGoogle Scholar
  • 84 Romero R, Nien J K, Espinoza J et al.. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.  J Matern Fetal Neonatal Med. 2008;  21(1) 9-23
    CrossrefPubMedGoogle Scholar
  • 85 Morbidelli L, Chang C H, Douglas J G, Granger H J, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium.  Am J Physiol. 1996;  270(1 Pt 2) H411-H415
    PubMedGoogle Scholar
  • 86 He H, Venema V J, Gu X, Venema R C, Marrero M B, Caldwell R B. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src.  J Biol Chem. 1999;  274(35) 25130-25135
    CrossrefPubMedGoogle Scholar
  • 87 Kim Y G, Suga S I, Kang D H et al.. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy.  Kidney Int. 2000;  58(6) 2390-2399
    CrossrefPubMedGoogle Scholar
  • 88 Masuda Y, Shimizu A, Mori T et al.. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis.  Am J Pathol. 2001;  159(2) 599-608
    CrossrefPubMedGoogle Scholar
  • 89 Kang D H, Kim Y G, Andoh T F et al.. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor.  Am J Physiol Renal Physiol. 2001;  280(4) F727-F736
    PubMedGoogle Scholar
  • 90 Yang J C, Haworth L, Sherry R M et al.. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.  N Engl J Med. 2003;  349(5) 427-434
    CrossrefPubMedGoogle Scholar
  • 91 Eremina V, Jefferson J A, Kowalewska J et al.. VEGF inhibition and renal thrombotic microangiopathy.  N Engl J Med. 2008;  358(11) 1129-1136
    CrossrefPubMedGoogle Scholar
  • 92 Patel T V, Morgan J A, Demetri G D et al.. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.  J Natl Cancer Inst. 2008;  100(4) 282-284
    PubMedGoogle Scholar
  • 93 Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro.  J Cell Biol. 1998;  140(4) 947-959
    CrossrefPubMedGoogle Scholar
  • 94 Eremina V, Sood M, Haigh J et al.. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.  J Clin Invest. 2003;  111(5) 707-716
    CrossrefPubMedGoogle Scholar
  • 95 Bergmann A, Ahmad S, Cudmore M et al.. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model.  J Cell Mol Med. 2009;  , June 16 (Epub ahead of print)
    Google Scholar
  • 96 Gilbert J S, Verzwyvelt J, Colson D et al.. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension.  Hypertension. 2010;  55(2) 380-385
    CrossrefPubMedGoogle Scholar
  • 97 Li Z, Zhang Y, Ying Ma J et al.. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.  Hypertension. 2007;  50(4) 686-692
    CrossrefPubMedGoogle Scholar
  • 98 Powers R W, Roberts J M, Cooper K M et al.. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia.  Am J Obstet Gynecol. 2005;  193(1) 185-191
    CrossrefPubMedGoogle Scholar
  • 99 Parikh S M, Karumanchi S A. Putting pressure on pre-eclampsia.  Nat Med. 2008;  14(8) 810-812
    CrossrefPubMedGoogle Scholar
  • 100 Heydarian M, McCaffrey T, Florea L et al.. Novel splice variants of sFlt1 are upregulated in preeclampsia.  Placenta. 2009;  30(3) 250-255
    CrossrefPubMedGoogle Scholar
  • 101 Sela S, Itin A, Natanson-Yaron S et al.. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia.  Circ Res. 2008;  102(12) 1566-1574
    CrossrefPubMedGoogle Scholar
  • 102 Thomas C P, Andrews J I, Liu K Z. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta.  FASEB J. 2007;  21(14) 3885-3895
    CrossrefPubMedGoogle Scholar
  • 103 Karumanchi S A, Maynard S E, Stillman I E, Epstein F H, Sukhatme V P. Preeclampsia: a renal perspective.  Kidney Int. 2005;  67(6) 2101-2113
    CrossrefPubMedGoogle Scholar
  • 104 Wallukat G, Homuth V, Fischer T et al.. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor.  J Clin Invest. 1999;  103(7) 945-952
    CrossrefPubMedGoogle Scholar
  • 105 Gant N F, Daley G L, Chand S, Whalley P J, MacDonald P C. A study of angiotensin II pressor response throughout primigravid pregnancy.  J Clin Invest. 1973;  52(11) 2682-2689
    CrossrefPubMedGoogle Scholar
  • 106 Dechend R, Homuth V, Wallukat G et al.. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor.  Circulation. 2000;  101(20) 2382-2387
    CrossrefPubMedGoogle Scholar
  • 107 Zhou C C, Zhang Y, Irani R A et al.. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice.  Nat Med. 2008;  14(8) 855-862
    CrossrefPubMedGoogle Scholar
  • 108 Zhou C C, Ahmad S, Mi T et al.. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling.  Hypertension. 2008;  51(4) 1010-1019
    CrossrefPubMedGoogle Scholar
  • 109 Herse F, Dechend R, Harsem N K et al.. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia.  Hypertension. 2007;  49(3) 604-611
    CrossrefPubMedGoogle Scholar
  • 110 Dechend R, Müller D N, Wallukat G et al.. AT1 receptor agonistic antibodies, hypertension, and preeclampsia.  Semin Nephrol. 2004;  24(6) 571-579
    CrossrefPubMedGoogle Scholar
  • 111 Dragun D, Müller D N, Bräsen J H et al.. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.  N Engl J Med. 2005;  352(6) 558-569
    CrossrefPubMedGoogle Scholar
  • 112 Walther T, Wallukat G, Jank A et al.. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature.  Hypertension. 2005;  46(6) 1275-1279
    CrossrefPubMedGoogle Scholar
  • 113 Baschat A A, Hecher K. Fetal growth restriction due to placental disease.  Semin Perinatol. 2004;  28(1) 67-80
    CrossrefPubMedGoogle Scholar
  • 114 Mayhew T M, Wijesekara J, Baker P N, Ong S S. Morphometric evidence that villous development and fetoplacental angiogenesis are compromised by intrauterine growth restriction but not by pre-eclampsia.  Placenta. 2004;  25(10) 829-833
    CrossrefPubMedGoogle Scholar
  • 115 Chaddha V, Viero S, Huppertz B, Kingdom J. Developmental biology of the placenta and the origins of placental insufficiency.  Semin Fetal Neonatal Med. 2004;  9(5) 357-369
    CrossrefPubMedGoogle Scholar
  • 116 Pardi G, Marconi A M, Cetin I. Placental-fetal interrelationship in IUGR fetuses—a review.  Placenta. 2002;  23(suppl A) S136-141
    CrossrefPubMedGoogle Scholar
  • 117 DeChiara T M, Efstratiadis A, Robertson E J. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting.  Nature. 1990;  345(6270) 78-80
    CrossrefPubMedGoogle Scholar
  • 118 Crossey P A, Pillai C C, Miell J P. Altered placental development and intrauterine growth restriction in IGF binding protein-1 transgenic mice.  J Clin Invest. 2002;  110(3) 411-418
    PubMedGoogle Scholar
  • 119 Baker J, Liu J P, Robertson E J, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth.  Cell. 1993;  75(1) 73-82
    CrossrefPubMedGoogle Scholar
  • 120 Abuzzahab M J, Schneider A, Goddard A Intrauterine Growth Retardation (IUGR) Study Group et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation.  N Engl J Med. 2003;  349(23) 2211-2222
    CrossrefPubMedGoogle Scholar
  • 121 Lopez-Lopez C, LeRoith D, Torres-Aleman I. Insulin-like growth factor I is required for vessel remodeling in the adult brain.  Proc Natl Acad Sci U S A. 2004;  101(26) 9833-9838
    CrossrefPubMedGoogle Scholar
  • 122 Herr F, Liang O D, Herrero J et al.. Possible angiogenic roles of insulin-like growth factor II and its receptors in uterine vascular adaptation to pregnancy.  J Clin Endocrinol Metab. 2003;  88(10) 4811-4817
    CrossrefPubMedGoogle Scholar
  • 123 Rabinovsky E D, Draghia-Akli R. Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis.  Mol Ther. 2004;  9(1) 46-55
    PubMedGoogle Scholar
  • 124 Krantz D, Goetzl L, Simpson J L First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.  Am J Obstet Gynecol. 2004;  191(4) 1452-1458
    CrossrefPubMedGoogle Scholar
  • 125 Smith G C, Stenhouse E J, Crossley J A, Aitken D A, Cameron A D, Connor J M. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth.  J Clin Endocrinol Metab. 2002;  87(4) 1762-1767
    CrossrefPubMedGoogle Scholar
  • 126 Shibata E, Rajakumar A, Powers R W et al.. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor.  J Clin Endocrinol Metab. 2005;  90(8) 4895-4903
    CrossrefPubMedGoogle Scholar
  • 127 Malamitsi-Puchner A, Boutsikou T, Economou E et al.. The role of the anti-angiogenic factor endostatin in intrauterine growth restriction.  J Soc Gynecol Investig. 2005;  12(3) 195-197
    CrossrefPubMedGoogle Scholar
  • 128 Lepercq J, Guerre-Millo M, André J, Caüzac M, Hauguel-de Mouzon S. Leptin: a potential marker of placental insufficiency.  Gynecol Obstet Invest. 2003;  55(3) 151-155
    CrossrefPubMedGoogle Scholar
  • 129 Savvidou M D, Hingorani A D, Tsikas D, Frölich J C, Vallance P, Nicolaides K H. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia.  Lancet. 2003;  361(9368) 1511-1517
    CrossrefPubMedGoogle Scholar
  • 130 Lachmeijer A M, Dekker G A, Pals G, Aarnoudse J G, ten Kate L P, Arngrímsson R. Searching for preeclampsia genes: the current position.  Eur J Obstet Gynecol Reprod Biol. 2002;  105(2) 94-113
    PubMedGoogle Scholar
  • 131 Lam C, Lim K H, Karumanchi S A. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia.  Hypertension. 2005;  46(5) 1077-1085
    CrossrefPubMedGoogle Scholar

S. Ananth KarumanchiM.D. 

Beth Israel Deaconess Medical Center

99 Brookline Avenue, Boston, MA 02215

Email: sananth@bidmc.harvard.edu

      >